4.5 Review

Heart failure as a general pandemic in Asia

Journal

EUROPEAN JOURNAL OF HEART FAILURE
Volume 17, Issue 9, Pages 884-892

Publisher

WILEY
DOI: 10.1002/ejhf.319

Keywords

Heart failure; Ageing; Asia; Prevention

Funding

  1. Bayer Yakuhin, Ltd (Osaka, Japan)
  2. Daiichi Sankyo Co., Ltd (Tokyo, Japan)
  3. Novartis Pharma K.K. (Tokyo, Japan)
  4. Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan)
  5. Kowa Pharmaceutical Co., Ltd (Tokyo, Japan)
  6. Dainippon Sumitomo Pharma, Co., Ltd (Osaka, Japan),
  7. Nippon Boehringer Ingelheim Co., Ltd (Tokyo, Japan)

Ask authors/readers for more resources

Heart failure (HF) is epidemic in healthcare worldwide, including Asia. It appears that HF will become more serious in the near future, with the epidemiological transition and ageing of the population. However, in contrast to Western countries, information on HF epidemiology is still limited in Asia, particularly in South Asia. In this review, we will briefly summarize available information regarding the current and future burden of HF in Asia, which indicates the importance of both primary prevention of underlying diseases of HF and secondary prevention, including management of ischaemic HF, HF with preserved EF, and HF in the elderly.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available